Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|March 25, 2020
A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Advertisement
Case: A 63-Year-Old Woman With MetastaticEGFR+ NSCLC
Initial presentation
- A 63-year-old woman presented with persistent cough, and a 5-lb weight loss
- PMH/SH: former smoker, quit 25 years ago
- PE: Decreased breath sounds on auscultation in the right lower lobe
Clinical workup
- Labs: WNL
- PFT: FEV1/FVC 60%; DLCO 68%
- Chest X-ray showed a right lower lobe soft tissue mass
- Chest/abdominal/pelvic CT showed a 3.8-cm solid pulmonary mass in the right lower lobe; enlarged contralateral hilar and mediastinal lymph nodes; 3 small right adrenal lesions noted
- CT‐guided core needle biopsy of the lung mass revealed lung adenocarcinoma; lymph node biopsy showed grade 2 adenocarcinoma
- Contrast‐enhanced MRI of the head showed no evidence of brain metastases
- Molecular testing:EGFRexon 21 substitution L858R, ALK-, BRAF-, ROS1-, RET-, MET-, ERBB2-,PD-L1 TPS 14%
- Staging- T2aN3M1b - IVA; ECOG PS 0
Treatment
- Patient was started on erlotinib 150 mg PO qDay + ramucirumab 10 mg/kg IV
- Imaging at 3-month showed partial response with decrease in lung lesion
Advertisement
Related to this article
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5